Page 19 - Q2 Results

SBI Card Q2 net profit jumps 52% to Rs 526 crore on low provisions

Impairment losses and bad debts declined 8 per cent YoY to Rs 546 crore but was up 21 per cent sequentially.

Tamilnad Mercantile Bank's Q2 net rises 37.15% to Rs 262.3 crore

TMB's NII was up 15.6 per cent YoY in Q2FY23 at Rs 508.16 crore

Airtel Africa profit after tax down 17.2% at $180 mn in Sept quarter

Airtel Africa's revenue grew 12.7 percent on a reported basis and 18.5 percent in constant currency, to $1,308 million in Q2 September 2022

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock

The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.

Indus Towers to raise Rs 2,000 crore via NCDs after weak Q2 result

The fund raise was approved by the company's board of directors following the second quarter FY 2023 result which saw 44 per cent year on year drop in net profit to Rs 872 crore.

F&O expiry: Sensex rises 213 pts, Nifty holds 17,750; metals rally, IT slip

CLOSING BELL: Tata Steel, Power Grid, Sun Pharma, Axis Bank, Bharti Airtel, Kotak Bank, M&M, HDFC, Dr Reddy's Labs, and Titan were the leading winners

Dabur to acquire 51% stake in Badshah Masala; stock rises 4%

The management said that the transaction is expected to be Cash EPS neutral in the first year and accretive thereafter.

Maruti Suzuki Q2 profit may surge up to 355% YoY on higher sales volume

Maruti Suzuki Q2 preview: The company, which is due to announce its result on Friday, October 28, could also see margin expansion due to price hikes, forex benefits, and operating leverage

Sun Pharma gains 2%, conquers Rs 1,000-mark after gap of over 7 years

The stock traded higher for the third straight day and has gained nearly 4 per cent during the period. It quoted at its highest level since May 2015.

Stocks to watch: Zee Ent, SBI Cards, Tata Chemicals, Glenmark Pharma, Dabur

Stocks to watch today: SBI Cards, Indus Towers will report July-September quarter results on Thursday, October 27; Sony India and Zee Ent plan to sell 3 Hindi channels to address anti-competition

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Century Textiles Q2 profit rises 59% to Rs 70 cr, total income jumps

Century Textiles and Industries, a part of the Aditya Birla Group, on Wednesday reported 59.38 per cent rise in consolidated net profit at Rs 69.97 crore for September quarter 2022-23. In the year-ago period, the profit stood at Rs 43.9 crore, the company said in a regulatory filing. Total income from operations rose to Rs 1,242.11 crore from Rs 1,034.27 crore in the corresponding period of the previous year. Total expenses also shot up to Rs 1,125.25 crore as against Rs 972.08 crore. The company is into textiles, pulp and paper and realty businesses.

Gland Pharma's Q2 net dips 20.14% to Rs 241.24 cr; India revenue down 42%

Gland Pharma Ltd on Wednesday reported a 20.14 per cent decline in consolidated net profit at Rs 241.24 crore for the second quarter ended September 30, on lower sales and higher expenses. The company had posted a consolidated net profit of Rs 302.08 crore in the same period last fiscal, Gland Pharma said in a regulatory filing. The consolidated revenue from operations during the period under review were at Rs 1,044.4 crore, as against Rs 1,080.47 crore in the year-ago period, it added. Total expenses were higher at Rs 785.95 crore, as compared to Rs 731 crore in the same period a year ago, the company said. Gland Pharma said revenue from its core markets of US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal. However, India revenue was down 42 per cent at Rs 72.6 crore, as compared to Rs 125.8 crore in the year-ago quarter, while the same for the 'rest of the world' market w

Tech Mahindra to consider interim dividend for FY23 in board meeting

The company, in its exchange filing last week, informed that the board of directors will consider a proposal for payment of interim dividend for the financial year 2022-2023, during its scheduled meet

Dabur Q2 profit slips 2.8% to Rs 490.86 cr; revenue up 6% at Rs 2,986.5 cr

Homegrown FMCG major Dabur India Ltd on Wednesday reported a 2.85 per cent decline in its consolidated net profit to Rs 490.86 crore for the second quarter ended September 30. The company had posted a net profit of Rs 505.31 crore in the July-September quarter a year ago, Dabur India said in a regulatory filing. However, its revenue from operations rose 6 per cent to Rs 2,986.49 crore during the quarter under review against Rs 2,817.58 crore in the corresponding quarter of the previous fiscal. Dabur India's total expenses increased 8.94 per cent to Rs 2,471.28 crore in the latest September quarter. The same stood at Rs 2,268.47 crore last year.

Ramkrishna Forgings PAT in Q2 at Rs 64 cr on account of higher revenues

Ramkrishna Forgings has reported 27 per cent growth in profit after tax (PAT) at Rs 64 crore for September quarter 2022-23 on account of higher revenues. It had clocked Rs 50.11 crore profit in July-September period a year ago, the company said in a statement on Wednesday. During the quarter under review, revenue rose to Rs 762.55 crore from Rs 578.93 crore in the year-ago period. In the first half (April-September) of the ongoing financial year, its PAT was Rs 111.20 crore, 48.81 per cent higher from Rs 74.72 crore in the year-ago period. In the six-month period, sales volume was 41,257 tonne, up 47.17 per cent over the year-ago period. Overall capacity utilization was 82.24 per cent for the second quarter of 2022-23. "Our robust and diverse business model has yielded sustained growth momentum because of improved product mix and strong customer demand, our operating revenue increased by 31.72 per cent year-on-year. Improved capacity utilization led to operating leverage resultin

Life insurers' retail protection biz down YoY, seen stabilising going ahead

Max Life bucks trend with 11% YoY growth in retail protection APE in Q2

ICICI Bank Q2: Analysts expect sustained outperformance, up to 24% upside

ICICI Bank Q2 result review: ICICI Bank shares hit record high of Rs 942.7 apiece as the lender outperformed peers on every metric in Q2FY23

CDSL Q2 net profit falls 7% to Rs 80 cr, total income rises 3% to Rs 170 cr

Leading depository CDSL has reported a 7 per cent decline in its consolidated net profit to Rs 80 crore in three months ended September 2022. In comparison, the depository had posted a net profit of Rs 86 crore in the year-ago period, Central Depository Services (India) Limited (CDSL) said in statement. The company's total income rose by 3 per cent to Rs 170 crore during the period under review. The same stood at Rs 165 crore in the second quarter ended September 30, 2021. According to the company, 48 lakh demat accounts were opened in the September quarter of the current fiscal. "The financial performance this quarter continues to be strengthened by our sustainable long-term strategy of investing in the digital eco-systems and robust technology to provide all market participants an easy and secured platform," CDSL MD and CEO Nehal Vora said. CDSL facilitates holding and transacting in securities in the electronic form as well as settlement of trades on stock exchanges. It mainta

Laurus Labs hits 4-month low; stock slips 14% in 3 days post mixed Q2FY23

Despite mixed Q2FY23 performance, brokerages retain their 'buy' rating on Laurus Labs with a target price in the range of Rs 610 and Rs 630 per share.